KR20080106789A - Glycyrrhiza extracts increasing immunity of animals and method for preparing thereof - Google Patents
Glycyrrhiza extracts increasing immunity of animals and method for preparing thereof Download PDFInfo
- Publication number
- KR20080106789A KR20080106789A KR1020070054645A KR20070054645A KR20080106789A KR 20080106789 A KR20080106789 A KR 20080106789A KR 1020070054645 A KR1020070054645 A KR 1020070054645A KR 20070054645 A KR20070054645 A KR 20070054645A KR 20080106789 A KR20080106789 A KR 20080106789A
- Authority
- KR
- South Korea
- Prior art keywords
- licorice
- extract
- iii
- minutes
- dried
- Prior art date
Links
- 241000202807 Glycyrrhiza Species 0.000 title claims abstract description 95
- 239000000284 extract Substances 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 12
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 241001465754 Metazoa Species 0.000 title abstract description 10
- 230000001965 increasing effect Effects 0.000 title abstract description 4
- 230000036039 immunity Effects 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 61
- 239000012153 distilled water Substances 0.000 claims abstract description 18
- 238000009835 boiling Methods 0.000 claims abstract description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 84
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 84
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 84
- 229940010454 licorice Drugs 0.000 claims description 84
- 229940069445 licorice extract Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 8
- 235000008216 herbs Nutrition 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000003674 animal food additive Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000000091 immunopotentiator Effects 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 4
- 238000007710 freezing Methods 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 description 32
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 24
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 241000283707 Capra Species 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 102000008070 Interferon-gamma Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000001569 carbon dioxide Substances 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940044627 gamma-interferon Drugs 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 150000002978 peroxides Chemical class 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000007123 defense Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229920000392 Zymosan Polymers 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000005965 immune activity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002766 immunoenhancing effect Effects 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 동물의 면역능을 증강시키는 감초 추출물에 관한 것이다.The present invention relates to a licorice extract that enhances the immune ability of the animal.
동물에서 각종 병원미생물 침입에 1차적으로 저항할 수 있는 면역을 담당하는 것은 체내에 있는 주요 면역세포인 호중구(neutrophil), 대식구(macrophages), 림프구(lymphocytes) 등이며 이들의 활성이 비정상적일때 병원미생물이 감염, 증식하여 발병하게 된다. 면역증강물질은 이러한 질병방어에 주요 역할을 담당하고 있는 각종 면역세포의 기능을 증강시켜 질병감염에 대한 저항성을 높혀 준다. 이러한 면역증강물질은 각종 동물, 식물, 미생물 등 다양한 생물체에 존재하는 것으로 알려져 있으며 이들로부터 추출한 많은 물질이 사람 및 동물의 면역증강제로서 개발되어 사용되고 있다.In animals, the primary resistance to the invasion of various pathogenic microorganisms is neutrophils, macrophages, and lymphocytes, which are the main immune cells in the body, and pathogenic microorganisms when their activity is abnormal. This infection, proliferation, and onset. Immunopotentiating substances enhance the resistance to disease infection by enhancing the function of various immune cells that play a major role in defense against such diseases. These immune enhancing substances are known to exist in various organisms such as various animals, plants, and microorganisms, and many substances extracted therefrom have been developed and used as immune enhancers for humans and animals.
감초(Glycyrrhiza)는 장미목 콩과의 약용식물로서, 뿌리는 적갈색으로 땅속 깊이 내려가고 모난 줄기는 1~1.5m 정도로 곧게 자라는데 흰털이 총총이 나서 회백색으로 보인다. 잎은 겹잎으로 어긋나며, 여름에 나비 모양의 쪽빛을 띤 보라색 꽃 이 핀다. 붉은 갈색의 뿌리는 단맛이 나서 감미료 또는 약재로 사용되며 한방에서는 모든 처방에 골고루 쓰이는 한약재이다. 중국의 동북부, 몽골이 원산지로 세계 각지에서 약초로 재배한다. 감초는 유효성분으로 그라이시리진(Glycyrrhizin)이 알려져 있으며, 그 외의 성분이 위액분비 억제 및 궤양수복 작용도 하는 것으로 인정되고 있다. 또한 감초 엑기스에는 에스트로겐양작용, 진해작용, 항염증작용, 항알러지작용, 해독작용, 고지혈증 개선작용 등이 있는 것으로 밝혀져 있다.Licorice (Glycyrrhiza) is a medicinal plant of the Rosacea legume, whose roots are reddish brown and deep in the ground, and the stalks grow straight by 1 to 1.5m. The leaves are alternated with the double leaves, and in summer, butterfly-shaped indigo purple flowers bloom. The reddish brown root is sweet and is used as a sweetener or medicinal herb. Herbal medicine is evenly used in all medicines. Mongolia, the northeastern part of China, is native to the world and is grown as a herb. Licorice is known as Glycyrrhizin as an active ingredient, and other ingredients are recognized to inhibit gastric secretion and ulcerative action. Licorice extract has also been found to have estrogen-positive, antitussive, anti-inflammatory, anti-allergic, detoxification, and hyperlipidemic effects.
인삼, 버섯 등 다양한 식물로부터 면역증강물질을 추출하여 활용하고 있으나, 한약재인 감초에서 면역증강물질을 추출하여 주요 면역세포인 호중구, 대식구 및 림프구(비장세포)에서의 면역활성 증강효능과 병원균에 대한 비특이적 방어능 향상에 관한 기술개발 등은 현재까지 보고된 바 없다.Immune enhancers are extracted from various plants such as ginseng and mushrooms, but the immune enhancers are extracted from licorice, which is a herbal medicine, to enhance immune activity and pathogens in neutrophils, macrophages, and lymphocytes (splenocytes). There have been no reports on the development of technologies related to nonspecific defense enhancement.
이에 본 발명자들은 한약재인 감초로부터 물리적인 방법으로 신규한 유용물질을 추출하여 추출물의 각종 면역세포의 활성에 미치는 효과를 시험하여 추출물질의 우수한 면역증강활성을 확인하고 본 발명을 완성하기에 이르렀다.Therefore, the present inventors extracted the new useful substance from the licorice, which is a herbal medicine, and tested the effect on the activity of various immune cells of the extract to confirm the excellent immune enhancing activity of the extract and came to complete the present invention.
따라서, 본 발명의 목적은 감초로부터 추출한 동물의 면역능을 향상시킬 수 있는 신규한 물질을 제공하고, 동물의 면역증강 활성이 우수한 상기 감초 추출물을 이용하여 동물용 면역증강제, 백신보좌제, 보조치료제 등을 개발하는데 활용될 수 있도록 하는 것이다.Therefore, an object of the present invention is to provide a novel substance that can improve the immune ability of the animal extracted from licorice, and using the licorice extract excellent in the animal's immune enhancing activity, animal enhancers, vaccine adjuvant, adjuvant therapy, etc. It can be used to develop
상기한 목적을 달성하기 위하여, 본 발명은 면역증강 효능이 있는 감초 열탕추출물 및 상기 면역증강 효능이 있는 감초 열탕추출물을 제조하는 방법을 제공한다.In order to achieve the above object, the present invention provides a licorice hot water extract with immuno-enhancing efficacy and a method for producing the licorice hot water extract with immuno-enhancing efficacy.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에서 제공되는 감초 열탕추출물은 Licorice hot water extract provided in the present invention
(ⅰ) 마른 감초 100g당 증류수 1000ml를 넣고 20~30분간 감초를 불린 다음 150분간 약재를 달인 후 추출액을 모으는 단계;(Iii) adding 1000 ml of distilled water per 100 g of dried licorice, soaking licorice for 20-30 minutes, and then decocting the medicine for 150 minutes to collect the extract;
(ⅱ) 상기 (ⅰ)의 달인 후의 감초에 마른 감초 100g당 증류수 800ml를 넣고 150분간 약재를 달인 후 추출액을 모으는 단계;(Ii) adding 800 ml of distilled water per 100 g of dried licorice to the licorice after decoction of (iii), decocting the medicinal herbs for 150 minutes, and collecting the extract;
(ⅲ) 상기 (ⅱ)의 달인 후의 감초에 마른 감초 100g당 증류수 700ml를 넣고 150분간 약재를 달인 후 추출액을 모으는 단계; (Iii) adding 700 ml of distilled water per 100 g of dried licorice to the licorice after decoction of (ii), decocting medicinal herbs for 150 minutes, and collecting the extract;
(ⅳ) 상기 (ⅰ), (ⅱ) 및 (ⅲ) 단계에서 추출한 추출액을 모아서 농축시키는 단계; 및(Iii) collecting and concentrating the extract extracted in steps (iii), (ii) and (iii); And
(ⅴ) 상기 (ⅳ) 단계에서 농축한 감초 추출액을 동결 건조시키는 단계;(Iii) freeze drying the licorice extract concentrated in step (iii);
의 과정을 통하여 제조된다.It is manufactured through the process of.
마른 감초 100g에서 열탕추출물을 제조할 경우, 상기 (ⅳ) 단계에서 3회 추출한 추출액을 100ml로 농축시킨다.When the hot water extract is prepared from 100 g of dry licorice, the extract extracted three times in the step (iii) is concentrated to 100 ml.
상기 감초 열탕추출물은 면역증강제, 백신의 효능을 향상시킬 수 있는 첨가물로서 사용되는 백신보좌제(adjuvants), 치료 효능을 증강시킬 수 있는 보조치료 제, 사료첨가제 등의 용도로 이용될 수 있다.The licorice hot water extract may be used as an adjuvant, an adjuvants used as an additive to improve the efficacy of the vaccine, an adjuvant to enhance the therapeutic efficacy, and a feed additive.
면역증강제의 경우는 본 발명이 제공하는 감초 열탕추출물을 동결건조형태로 생산하여 사용시 희석액에 부유하여 주사로 사용되게 되며, 백신보좌제인 경우는 백신의 보좌제로 사용하는 오일(oil)이나 알루미늄 겔(aluminium gel)에 흡착시켜 사용하게 된다. 보조치료제의 경우는 면역증강제의 경우와 동일하며, 사료첨가제로 사용되는 경우는 본 발명이 제공하는 감초 열탕추출물을 건조하여 분말형태로 만들어 사료에 첨가하여 사용하게 된다.In the case of an immunopotentiator, the licorice hot water extract provided by the present invention is produced in a lyophilized form, suspended in a diluent when used, and used as an injection. It is adsorbed on aluminum gel). In the case of adjuvant therapy is the same as in the case of an immune enhancer, when used as a feed additive is to use the licorice hot water extract provided by the present invention to make a powder form added to the feed.
면역증강효능을 나타내기 위한 감초 열탕추출물의 사용량은 면역세포 및 동물의 종류에 따라 다르나, 면역증강제, 백신보좌제, 보조치료제 또는 사료첨가제 등의 제형내에서 사용시 제형의 부피를 기준으로 10㎍/㎖~1㎎/㎖인 것이 바람직하고, 면역세포 시험은 면역증강물질을 선발하는 과정으로 간주할 때, 실제 적용 농도는 실험동물에서의 유효농도를 기준으로 하여야 할 것이므로 제형의 부피를 기준으로 100㎍/㎖인 것이 더욱 바람직하다.The amount of licorice hot water extract used to show the immunopotentiation effect varies depending on the type of immune cells and animals, but it is 10 ㎍ / based on the volume of the formulation when used in the formulation of an immune enhancer, vaccine supplement, adjuvant or feed additive. It is preferable that the concentration is between 1 and 1 mg / ml, and when the immune cell test is regarded as a process for selecting an adjuvant, the actual applied concentration should be based on the effective concentration in the experimental animal. It is more preferable that it is μg / ml.
이하, 실시예 및 실험예를 통하여 본 발명을 더욱 상세히 설명하지만, 본 발명이 이들 예로만 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited only to these examples.
[참고예 1] 감초 열탕추출물 준비Reference Example 1 Preparation of Licorice Boiled Extract
열탕추출법에 의하여 다음과 같이 추출물을 준비하였다. 감초 100g을 물에 씻어 먼지를 제거하였으며, 이 때 대부분의 약제가 수용성이기 때문에 오래 씻으면 약의 유효성분이 유출되므로 가급적 가볍게 살짝 씻도록 하였다. 씻은 감초를 열탕용 흰 봉지에 약재 및 증류수 1000ml를 넣고 약 20~30분간 담가 두어 약을 불린 다음에 150분간 약재를 달인 후 추출액을 모아두었다. 다시 증류수 800ml를 넣고 150분간 약재를 달인 후 추출액을 모으고 다시 증류수 700ml를 넣어 150분간 약재를 달인 후 추출액을 모아두었으며, 3회 추출한 추출액을 모아서 100ml로 농축시켰다. 이 때 농축액이 타지 않도록 주의하며, 탄 경우 버리고 다시 추출하도록 하였다. 100ml로 농축한 추출액을 동결 건조시키고, 건조된 추출물의 무게를 측정하였다. 상기한 추출법으로 추출한 감초추출물의 함량은 다음과 같았다. 즉, The extract was prepared by boiling water extraction as follows. 100 g of licorice was washed in water to remove dust. At this time, since most of the drugs are water-soluble, the active ingredients of the drug were spilled over a long period of time, so that they were lightly washed. Washed licorice was put in a white bag for boiling water and put 1000ml of medicinal herbs and distilled water, soaked for about 20-30 minutes, soaked the medicine and then decocted the medicine for 150 minutes and collected the extract. Then, 800 ml of distilled water was added and the extracts were extracted for 150 minutes, the extracts were collected. Then, 700 ml of distilled water was added, the extracts were collected for 150 minutes, and the extracts were collected. The extracts were collected three times and concentrated to 100 ml. At this time, be careful not to burn the concentrate, and if burned, discarded and extracted again. The extract, concentrated to 100 ml, was lyophilized and the weight of the dried extract was measured. Licorice extract content extracted by the above extraction method was as follows. In other words,
시료 농출량; 100ml Sample concentration; 100 ml
건조량; 3.08g/20ml Dryness; 3.08g / 20ml
추출효율; 15.4g/100g(%)Extraction efficiency; 15.4 g / 100 g (%)
이었다.It was.
[실험예 1] 감초 열탕추출물의 산양혈중 호중구(neutrophil)의 무작위유주능(Random migration) 증강효과[Experimental Example 1] Random Migration Enhancement Effect of Neutrophil in Goat Blood of Licorice Boiling Extract
1. 산양혈중 호중구 분리 및 분비 추출물로 혼합 처리1.Isolation of neutrophils in goat blood and mixed treatment with secretion extract
산양의 경정맥으로부터 혈액을 채혈하여 항응고제인 에이시디액(ACD, sodium citrate, citric acid, dextrose)과 혼합하고 2,500 × g, 20분 원심분리하여 연막(buffy coat)을 제거 후 적혈구를 용혈시켜 1500 × g, 5분 원심분리하여 호중구를 수집한 다음 알피엠아이(RPMI1640)배지에 호중구수가 1 × 107/ml 되도록 부유 하여 시험에 사용하였다. 감초 열탕추출물로 호중구를 혼합처리하기 위하여 냉장보관 중인 건조시킨 추출물을 알피엠아이배지로 1mg/ml 농도로 부유하여 10배(100㎍/ml), 100배(10㎍/ml)로 희석하고 같은 양(30㎕)의 호중구부유액(1 × 107/ml)과 혼합하여 탄산가스 배양기(CO2 incubator)에서 37℃, 1시간 혼합처리하였다.Blood is drawn from the goat's jugular vein and mixed with anticoagulant ACD (ACD, sodium citrate, citric acid, dextrose) and centrifuged at 2,500 × g for 20 minutes to remove the buffy coat and then hemolyzed red blood cells. The neutrophils were collected by centrifugation for 5 minutes, and then suspended in AlMPM medium (RPMI1640) so that the number of neutrophils was 1 × 10 7 / ml. In order to mix neutrophils with licorice hot water extract, the dried extract in cold storage was suspended at 1mg / ml with AlMPI medium, diluted 10 times (100㎍ / ml), 100 times (10㎍ / ml) and the same amount. (30 μl) of neutrophil suspension (1 × 107 / ml) was mixed and treated at 37 ° C. for 1 hour in a CO 2 incubator.
2. 무작위유주능(Random migration) 증강효과2. Effect of random migration
유주능이란, 세균이나 바이러스를 탐식하고자 그 곳으로 달려가는 면역세포의 힘으로, 유주능이 클수록 면역세포의 활성이 좋다는 것을 의미한다.Jujugi ability, the power of the immune cells running there to detect bacteria or viruses, the greater Jujugi ability means that the activity of the immune cells is better.
감초 열탕추출액과 혼합처리한 호중구 10㎕씩을 아가로즈 플레이트(agarose plate)에 직경 3mm되게 만든 홀(hole)에 넣고 탄산가스 배양기에서 37℃, 18시간 적용 후 8% 구루타알데하이드액으로 고정한 다음, 겔을 제거 후에 세척, 건조하였다. 건조시킨 플레이트를 스타트 염색액(Stat stain, Volu-Sol, Inc.)으로 염색하여 호중구가 유주한 거리를 현미경(MC-50T, MEIJI/Japan)으로 측정하고 호중구의 유주면적을 하기 수학식 1과 같이 계산하였다.10 μl of neutrophils mixed with licorice hot water extract were placed in a hole made 3 mm in diameter in an agarose plate, and fixed in 8% gurualdehyde solution after application at 37 ° C. for 18 hours in a carbon dioxide incubator. The gel was removed, washed and dried. The dried plate was stained with start stain (Stat stain, Volu-Sol, Inc.) to measure the distance of neutrophil drift under a microscope (MC-50T, MEIJI / Japan) Calculated together.
감초 열탕추출물로 희석 배수별로 처리한 산양 혈중 호중구의 무작위유주능에 미치는 영향은 표 1에서와 같다. The effects of random neutrophils on goat blood neutrophils treated by dilution multiples with licorice hot water extract are shown in Table 1.
감초 열탕추출물을 1mg/ml, 100㎍/ml, 10㎍/ml의 농도로 처리한 호중구의 유주면적이 각 15.45, 17.51, 21.28로 대조군의 13.66에 비하여 현저한 (p<0.01~0.05) 차이를 나타내었다. 이를 통해 감초 열탕 추출물을 처리한 경우 호중구의 면역 활성이 대조군에 비하여 좋다는 것을 확인할 수 있었다.The area of neutrophils treated with licorice hot water extract at concentrations of 1 mg / ml, 100 µg / ml and 10 µg / ml was 15.45, 17.51 and 21.28, respectively, showing a significant (p <0.01 ~ 0.05) difference compared to 13.66 of the control group. It was. When the licorice boiled water extract was treated, the immune activity of neutrophils was confirmed to be better than that of the control group.
[실험예 2] 감초 열탕추출물의 산양혈중 호중구(neutrophil)의 지향성유주능(Directional migration) 증강효과 조사Experimental Example 2 Investigation of Enhancement of Directional Migration of Neutrophil in Goat Blood of Licorice Boiling Extract
실험예 1의 무작위유주능 증강효과를 조사하는 것과 같은 방법으로 감초 열탕추출물과 혼합처리한 호중구 10㎕를 아가로즈 플레이트(agarose plate)에 직경 3mm되게 일렬로 만든 3개의 홀(hole)중 가운데 홀에 넣고 나머지 두 홀에는 10㎕의 인산완충식염수액(PBS, pH 7.2)과 자이모산(Zymosan A, Sigma Z-4250)으로 옵소닌(opsonization) 처리한 염소보체를 각기 넣은 다음, 탄산가스배양기에서 37℃, 3~5시간 적용 후 8% 구루타알테하이드액으로 고정하고 겔을 제거한 다음에 세척, 건조하였다. 건조시킨 플레이트를 스타트 염색액(Stat stain, Volu-Sol, Inc.)으로 염색하여 인산완충식염수액과 옵소닌 처리 염소보체쪽으로 호중구가 유주한 거리를 각각 현미경(MC-50T, MEIJI/Japan)으로 측정하고 호중구의 유주거리 차이를 하기 수학식 2와 같이 계산하였다.The middle hole of three holes in which 10 μl of neutrophils mixed with licorice boiling water extract were mixed in agarose plate with a diameter of 3 mm in agarose plate in the same manner as in the investigation of the random potency enhancement effect of Experimental Example 1 Into the other two holes, put 10 ml of phosphate buffered saline solution (PBS, pH 7.2) and chlorine complement which was opsonized with Zymosan A (Zymosan A, Sigma Z-4250), and then in a carbon dioxide incubator. After application at 37 ° C. for 3 to 5 hours, the mixture was fixed with 8% gurualaldehyde solution, the gel was removed, washed and dried. The dried plate was stained with start stain (Stat stain, Volu-Sol, Inc.), and the distance of neutrophils to phosphate buffered saline and opsonine treated chlorine complement was measured under a microscope (MC-50T, MEIJI / Japan), respectively. Measured and the difference in the drift distance of the neutrophils was calculated as in Equation 2 below.
= 옵소닌 처리한 염소보체로 유주한 거리-인산완충식염수액으로 유주한 거리= Distance resident with opsonized chlorine complement-Distance phosphate buffered saline
희석 배수별 감초 열탕추출물로 처리한 산양 혈중 호중구의 지향성 유주능에 미치는 영향은 하기 표 2에서와 같다.The effects on the directed chemotactic ability of neutrophils in goat blood treated with licorice hot water extract by dilution multiples are shown in Table 2 below.
감초 열탕추출물(10㎍/ml)로 처리한 호중구의 지향성 유주거리가 1.75mm로서 대조군의 유주거리 1.24mm에 비하여 현저한 (p<0.01) 차이를 보였으며, 통계적으로 유의하지는 않았지만 감초 열탕추출물 100㎍으로 처리한 경우도 1.33mm로 대조군보다 유주거리가 컸다. 이를 통해 감초 열탕추출물을 처리한 경우 호중구의 면역활성이 대조군의 경우보다 좋다는 것을 확인할 수 있었다. The directional drift distance of neutrophils treated with licorice boiled extract (10㎍ / ml) was 1.75mm, which was remarkably (p <0.01) difference compared to 1.24mm of control vortex, and it was not statistically significant but 100㎍ of licorice boiled extract Also treated with 1.33mm was larger than the control drift distance. When the licorice boiled extract was treated, the immune activity of neutrophils was confirmed to be better than that of the control group.
[실험예 3] 감초 열탕 추출물의 산양혈중 호중구(neutrophil) 항미생물성 과산화물(superoxide, O2-) 산생능[Example 3] The antimicrobial peroxide goat blood neutrophils (neutrophil) of hot water extract of licorice (superoxide, O 2 -) acid saengneung
과산화물은 병원체인 세균 및 바이러스와 싸우고 독성 물질에 대한 해독작용을 하는 생체 방어 기능이 있다. 일반적으로 외부에서 세균이나 바이러스가 침투하면 항체를 만들어 싸우고나 직접 병원체를 공격하여 몸을 보호하게 되는데, 이 때 직접 공격하는 세포중 하나가 호중구이며, 병원체를 공격하는 과정에서 상당한 양의 과산화물을 만들어 적을 죽이게 된다.Peroxides have biological defenses that fight pathogens such as bacteria and viruses and detoxify toxic substances. In general, when bacteria or viruses penetrate from outside, they make antibodies to fight or directly attack pathogens to protect the body. At this time, one of the cells that attacks directly is neutrophils, and in the process of attacking the pathogens, a significant amount of peroxide is produced. Kill the enemy.
실험예 1의 무작위유주능 증강효과를 조사하는 것과 같은 방법으로 감초 열탕추출물과 혼합처리한 호중구(2 × 106/ml) 50㎕와 얼스액(Earls balanced salt solution, EBSS)과 염소보체로 옵소닌 처리한 자이모산 부유액 각 25㎕를 조배양용 마이크로플레이트(Costar, 96 well)의 홀에 넣고 탄산가스배양기에서 37℃, 1시간 작용시킨 후에 홀에 엔비티시액(NBT, nitroblue tetrazolium)을 100㎕(4mg/ml)씩 가하고 탄산가스배양기에서 3시간 반응시킨 다음 생성한 포르마잔(formazan)을 디엠에스오(DMSO) 100㎕를 가하여 녹인 후 흡수파장 560nm에서 흡광도를 엘라이자 판독기(ELISA reader, Titertec multiscan)로 판독하여 과산화물 생성양을 측정하였다. 감초 열탕추출물로 처리한 산양혈중 호중구의 과산화물 산생반응은 표 3과 같다.50 μl of neutrophils (2 × 10 6 / ml) mixed with licorice hot water extract, Earls balanced salt solution (EBSS), and chlorine complement 25 µl of each sonicated Zymosan suspension was placed in a hole of a co-culture microplate (Costar, 96 well) and operated at 37 ° C for 1 hour in a carbon dioxide incubator, followed by 100 µl of NBT (nitroblue tetrazolium) in the hole. (4mg / ml) was added and reacted for 3 hours in a carbon dioxide gas incubator. After dissolving formazan (formazan) in 100 μl of DMSO, absorbance was absorbed at an absorbing wavelength of 560 nm. ) And the amount of peroxide produced was measured. Peroxide production of neutrophils in goat blood treated with licorice hot water extract is shown in Table 3.
감초 열탕추출물 10㎍ 농도로 처리한 호중구의 과산화물 생성반응이 대조군에 비하여 현저히 (p<0.05) 높은 것을 확인할 수 있으며, 이를 통해 감초 열탕추출물을 처리한 경우 호중구의 활성이 증강된다는 것을 알 수 있었다.The peroxide generation reaction of neutrophils treated with 10 μg concentration of licorice hot water extract was significantly higher (p <0.05) compared to the control group, and it was found that the activity of neutrophils was enhanced when licorice hot water extract was treated.
[실험예 4] 감초 열탕추출물의 마우스 복강대식구(peritoneal macrophages) 산화질소(nitric oxide, NO) 산생능Experimental Example 4 Production of Mouse Peritoneal Macrophages Nitric Oxide (NO)
1. 마우스 복강대식구 분리1. Separation of mouse abdominal macrophage
25g의 아이시알(ICR, ♂) 마우스를 경추탈골법으로 처리하고 복강으로 5ml의 인산완충식염수(PBS, pH 7.2)를 주입하여 복강내 대식구를 수집하고 인산완충식염수로 2회 세척하여 세포수를 2 × 106/ml 되도록 알피엠아이 배지에 부유한 다음 조배양용 마이크로플레이트에 200㎕씩 분주하여 탄산가스배양기에서 37℃ 2시간 배양하였다. 배양 후 플레이트를 따뜻한 알피엠아이 배지로 3회 세척하여 플레이트에 부착하지 않은 세포를 제거하고 바닥에 부착한 대식구를 시험에 사용하였다.Treatment of 25g of Icyal (ICR, ♂) mice with cervical distal bone method and intraperitoneal injection of 5ml phosphate buffered saline (PBS, pH 7.2) to collect intraperitoneal macrophages and washing twice with phosphate buffered saline It was suspended in AlMPM medium to 2 × 10 6 / ml, and then 200 μl of the cultured microplate was incubated at 37 ° C. for 2 hours in a carbon dioxide gas incubator. After incubation, the plate was washed three times with warm ALPM medium to remove cells that did not adhere to the plate and macrophages attached to the bottom were used for the test.
2. 산화질소(NO) 산생능 조사2. Nitric oxide (NO) acid production investigation
대식구가 미생물을 탐식하면, 강력한 효소와 반응성 산소기(Reactive Oxygen Radicals, ROR) 또는 산화질소(NO)를 생산하여 탐식한 미생물을 처리하므로 산화질소 산생능을 측정하여 대식구의 활성 정도를 알 수 있다. When macrophages devour microorganisms, they produce powerful enzymes and reactive oxygen radicals (ROR) or nitric oxide (NO) to process the phagocytosis, and thus the nitric oxide activity can be measured to determine the activity of macrophages.
대식구가 있는 마이크로플레이트 각 홀에 알피엠아이배지로 감초 열탕추출물을 1mg/ml, 100㎍/ml 및 10㎍/ml가 되도록 희석하여 농도별로 각 50㎕씩 홀에 분주하고 탄산가스배양기(CO2 incubator)에서 37℃, 48시간 배양하였다. 각 홀의 상층액 100㎕와 그리스 시약(Griess reagent) 50㎕를 혼합하고 흡수파장 540nm에서 흡광도를 엘라이자 판독기(ELISA reader, Titertec multiscan)로 판독하여 표준액으로 사용한 아질산나트륨(sodium nitrite)의 표준곡선을 이용하여 산화질소 생성양을 측정하였다.A hot water extract of licorice rpm child medium in each hole microplate with macrophages 1mg / ml, 100㎍ / ml and 10㎍ / ml diluted so that the frequency division by the respective 50㎕ holes at different concentrations and the carbon dioxide gas incubator (CO 2 incubator Incubated at 37 ° C. for 48 hours. A standard curve of sodium nitrite used as a standard solution was obtained by mixing 100 μl of the supernatant of each hole and 50 μl of Greases reagent, and reading the absorbance at an absorbing wavelength of 540 nm using an ELISA reader (Titertec multiscan). The amount of nitric oxide produced was measured.
희석 배수별 감초 열탕추출물로 처리한 마우스 복강 대식구의 산화질소 산생능에 미치는 영향은 표 4에서와 같다. The effects on nitric oxide production of mouse peritoneal macrophages treated with licorice hot water extracts by dilution multiples are shown in Table 4.
감초 열탕추출물 1mg/ml, 100㎍/ml, 10㎍/ml으로 처리한 모든 마우스 복강 대식구 배양물에서 산화질소가 검출되었으며 100㎍으로 처리한 것이 가장 많은 0.78 micromole 이었다. 산화질소의 산생능이 증가한 것으로 감초 열탕추출물을 처리한 경우 대식구의 활성이 증강되었음을 확인할 수 있었다.Nitric oxide was detected in all mouse intraperitoneal macrophage cultures treated with licorice water extract 1mg / ml, 100µg / ml and 10µg / ml, with 0.78 micromole being the most. It was confirmed that the activity of macrophages was enhanced when the licorice hot water extract was treated with an increased acid production of nitric oxide.
[실험예 5] 감초 열탕추출물의 마우스 비장세포(spleen cell) 증생능(proliferation)Experimental Example 5 Mouse Spleen Cell Proliferation of Licorice Boiling Extract
1. 비장세포 분리1. Isolation of Splenocytes
25g의 아이시알(ICR, ♂) 마우스를 경추탈골법으로 처리하고 복벽을 절개하여 비장을 분리한 후 동망마쇠법으로 비장세포를 수집하였다. 비장세포에 혼재하여있는 적혈수를 용혈시켜 제거한 후 인산완충식염수로 2회 세척하여 세포수를 2 × 106/ml 되도록 알피엠아이 배지에 부유하고 조배양용 마이크로플레이트 각 홀에 100㎕씩 분주하였다.Igial (ICR, ♂) mouse of 25g was treated by cervical dislocation method, the abdominal wall was incised to separate the spleen, and the spleen cells were collected by the method of agitation. Red blood cells mixed in splenocytes were removed by hemolysis, washed twice with phosphate buffered saline, and suspended in AlfM medium so that the cell number was 2 × 10 6 / ml, and 100 μl was dispensed into each hole of the microplate for coculture.
2. 증생능 조사2. Proliferation investigation
비장세포의 증생능은 항체 생성 세포수를 증가시키는 것과 직접적인 관련이 있으며, 비장세포 수의 증가를 확인함으로써 면역기관의 주요 기능이 증진되었음을 확인할 수 있다.The proliferation of splenocytes is directly related to the increase in the number of antibody-producing cells, confirming the increase of the number of splenocytes, it can be confirmed that the main function of the immune system has been enhanced.
마우스 비장세포가 들어 있는 각 홀에 알피엠아이배지로 1mg/ml, 100㎍/ml 및 10㎍/ml가 되도록 희석한 감초 열탕추출물과 콘에이(Con A, 15㎍/ml)를 각 홀에 50㎕씩 첨가하고 탄산가스배양기에서 37℃, 48시간 배양하였다. 배양이 끝난 프레이트 각 홀에 엠티티시약(MTT, 4mg/ml) 50㎕씩을 가하고 탄산가스배양기에서 37℃, 4시간 반응시킨 후에 상층액을 제거하고 200㎕의 디엠에스오액(DMSO:EtOH=1:1) 200㎕와 소렌손 시액(Sorenson's buffer) 50㎕씩을 가하여 반응으로 생성된 포르마잔을 용해시켰다. 이것을 흡수파장 560nm에서 흡광도를 엘라이자 판독기(ELISA reader, Titertec multiscan)로 판독하여 분아능을 측정하였다.In each hole containing mouse splenocytes, licorice hot water extract and ConA (15 µg / ml) diluted to 1 mg / ml, 100 µg / ml and 10 µg / ml with RMP medium were added to each hole. Μl was added thereto and incubated for 48 hours at 37 ° C. in a carbon dioxide gas incubator. 50 μl of empty reagent (MTT, 4mg / ml) was added to each hole of the plate, and the supernatant was removed after 4 hours of reaction at 37 ° C. in a carbon dioxide incubator. 200 μl of DMS solution (DMSO: EtOH = 1: 1) 200 μl and 50 μl of Sorenson's buffer were added to dissolve the formazan produced in the reaction. The absorbance was read at an absorption wavelength of 560 nm with an ELISA reader (Titertec multiscan) to measure the germination capacity.
감초 열탕추출물의 희석 배수별로 처리한 마우스 비장세포의 증생능에 미치는 영향은 표 5에서와 같다. The effects on the growth capacity of mouse splenocytes treated by diluting folds of licorice hot water extract are shown in Table 5.
비장세포 증생능과 광학적 밀도는 비례한다. 상기 표 5에서 보면 1mg/ml, 100㎍/ml, 10㎍/ml 농도의 감초 열탕추출물로 처리한 경우 광학적 밀도가 대조군에 비하여 현저히 높다는 것을 확인할 수 있으며(p<0.01~0.05), 비장세포의 증생능이 대조군에 비하여 현저하게 높다고 볼 수 있다. 이를 통해 감초 열탕추출물을 처리한 경우 면역기관의 기능이 대조군에 비해 좋다는 것을 확인할 수 있었다.Splenocyte proliferation and optical density are proportional. In Table 5, it can be seen that the optical density was significantly higher than that of the control group when treated with licorice hot water extracts of 1 mg / ml, 100 µg / ml, and 10 µg / ml (p <0.01 ~ 0.05). The potentiation ability can be seen to be significantly higher than the control. This resulted in the treatment of licorice boiled water extract was confirmed that the function of the immune system is better than the control.
[실험예 6] 감초 열탕추출물의 마우스혈중 사이토카인(인터루킨-2 및 감마인터페론) 산생에 미치는 영향Experimental Example 6 Effect of Licorice Boiling Extract on the Production of Cytokines (Interleukin-2 and Gamma Interferon) in Mouse Blood
1. 감초 열탕추출물의 마우스 접종 및 채혈1. Mouse Inoculation and Blood Collection of Licorice Boiling Extract
감초 열탕추출물을 멸균증류수에 100㎍/ml 농도로 조제하고 25g의 아이시알(ICR, ♂) 마우스 복강으로 0.2ml를 2수에 접종한 다음 3일 후에 안와동맥으로부터 채혈하여 혈청을 분리한 즉시 냉동보관하면서 혈청 중의 사이토카인 양을 시험하였다.Licorice hot water extract was prepared in sterile distilled water at a concentration of 100 ㎍ / ml, inoculated with 0.2 g of two waters with 25 g of Icyal (ICR, ♂) mouse intraperitoneally, and then collected from the orbital artery after 3 days, and serum was immediately frozen. The amount of cytokine in serum was tested during storage.
2. 인터루킨-2 및 감마인터페론 생성양 조사2. Investigation of Interleukin-2 and Gamma Interferon Production
사이토카인이란 항원과 반응하는 등으로 인하여 활성화된 세포가 다른 세포에 작용하게 하는 활성물질로 인터루킨은 대식구나 림프구에서 분비되는 면역 조절 물질을 말하며, 이 중에서도 인터루킨-2는 T림프구 증식 및 분화, 세포독성림프구 및 대식구의 활성과 관련된 작용을 한다. 인터페론은 현재까지 알려진 것이 알파, 베타, 감마의 세 가지 종류인데 생산되는 세포에 따라 달리 부르고 있다. 즉 백혈구에서 생산되는 것은 인터페론 알파, 인터페론 베타, T림프구와 대과립구에서 생산되는 것은 인터페론 감마라 부른다. 인터페론의 주요 3가지 기능은 항바이러스 작용, 항증식 작용 및 면역조절작용이다.Cytokines are active substances that cause activated cells to act on other cells by reacting with an antigen. Interleukin is an immunomodulatory substance secreted from macrophages or lymphocytes. Among them, interleukin-2 is a T lymphocyte proliferation and differentiation cell. It is associated with the activity of toxic lymphocytes and macrophages. There are three known types of interferon, alpha, beta, and gamma, depending on the cells produced. In other words, what is produced in white blood cells is called interferon alpha, interferon beta, T lymphocytes, and macrophages are called interferon gamma. The three main functions of interferon are antiviral action, antiproliferative action and immunomodulatory action.
마우스 혈청중의 인터루킨-2 및 감마인터페론 생성양 조사는 인스턴트 엘라이자 킷트(Bender MedSystems, Austria)를 이용하였다. 즉, 희석액으로 2배로 희석한 혈청 50㎕와 100㎕의 증류수를 종류별 사이토카인 킷트의 마이크로플레이트 홀에 가하고 실온에서 3시간 반응시킨 후 세척액(wash buffer)으로 6회 세척하였다. 여기에 티엠비기질액(TMB substrate solution) 100㎕씩을 가하고 실온에서 10분 발색시킨 후에 100㎕씩의 반응중지액(stop solution)을 가한 다음 흡수파장 450nm에서 흡광도를 엘라이자 판독기(ELISA reader, Titertec multiscan)로 판독하고 표준품의 표준곡선을 이용하여 인터루킨-2 및 감마인터페론 생성양을 측정하였다.Interleukin-2 and gamma interferon production in the mouse serum was investigated using the instant eliza kit (Bender MedSystems, Austria). That is, 50 μl of serum diluted twice with diluent and 100 μl of distilled water were added to the microplate hole of the cytokine kit for each kind, and reacted for 3 hours at room temperature, and then washed 6 times with a wash buffer. 100 μl of TMB substrate solution was added thereto, followed by 10 minutes of color development at room temperature. Then, 100 μl of stop solution was added, and the absorbance was measured at an absorbing wavelength of 450 nm (ELISA reader, Titertec multiscan). ) And the production amount of interleukin-2 and gamma interferon using the standard curve of the standard.
감초 열탕추출물을 접종한 마우스 혈중 사이토카인 산생양은 하기 표 6과 같다.Cytokine acid production in mice inoculated with licorice water extract is shown in Table 6 below.
감초 열탕추출물을 접종한 경우 감마인터페론은 15.6피코그람(pg/ml)이 검출되었으나, 인터루킨-2의 검출양은 7.81피코그람 이하였다. 이를 통해 대조군에 비하여 혈중 사이토카인 산생능이 향상하였음을 확인할 수 있으며, 특히 감마인터페론의 산생능이 증가하였음을 확인할 수 있었다.Gamma interferon was detected at 15.6 picograms (pg / ml) when inoculated with licorice extract, but the amount of interleukin-2 was less than 7.81 picograms. As a result, it was confirmed that the cytokine acid production in blood was improved compared to the control group, and in particular, the acid production of gamma interferon was increased.
[실험예 7] 감초 열탕추출물의 병원성 포도상구균(pathogenic Staphylococcus aureus) 공격접종에 대한 방어능Experimental Example 7 Protective Activity against Licorice Boiling Extract of Pathogenic Staphylococcus aureus
병원성 포도상구균을 마우스에 접종하여 비특이적 방어능에 대하여 실험하였다.Pathogenic staphylococci were inoculated into mice and tested for nonspecific protective ability.
감초 열탕추출물을 멸균증류수에 100㎍/ml 농도로 조제하고 25g의 아이시알(ICR, ♂) 마우스 복강으로 0.2ml를 4수에 접종한 다음 3일 후에 병원성 포도상구균(Staphylococcus aureus, strain 289)으로 최소치사량의 10배(10MLD/0.3ml)양을 복강으로 공격접종하고 5일간의 생존율로 방어효과를 조사하였다. 결과는 하기 표 7에 나타내었다.Licorice hot water extract was prepared in sterile distilled water at a concentration of 100 ㎍ / ml, inoculated with 0.2 g of 4 water with 25 g of Icyal (ICR, ♂) mouse intraperitoneally, and after 3 days with Staphylococcus aureus (strain 289). Ten times (10MLD / 0.3ml) of the minimum lethal dose was inoculated into the abdominal cavity and the protective effect was investigated at 5 days survival rate. The results are shown in Table 7 below.
감초 열탕추출물을 접종한 마우스는 병원성 포도상구균 공격접종에서 모두 생존하여 100%의 방어율을 나타내었으며, 대조군 마우스는 모두 폐사하여 감초 열탕추출물의 우수한 비특이적 방어능을 확인할 수 있었다.The mice inoculated with licorice boiled extract survived all pathogenic staphylococcus challenge and exhibited a 100% protection rate, and all of the control mice died and confirmed excellent non-specific defense ability of the licorice boiled extract.
본 발명이 제공하는 감초 열탕추출물을 이용하여 동물의 질병을 효율적으로 치료, 예방할 수 있는 면역증강제, 백신의 효능을 향상시킬 수 있는 보좌제(adjuvants) 및 치료효능을 증강시킬 수 있는 보조치료제로서 활용효과가 높을 것으로 기대되며 이에 따른 양축농가의 가축질병으로 인한 경제적 피해를 크게 감소시킬 수 있을 뿐만 아니라 수입 동물용의약품과의 경쟁력도 강화될 수 있을 것이다.By using the licorice hot water extract provided by the present invention, it can be used as an adjuvant that can effectively treat and prevent animal diseases, as an adjuvants that can improve the efficacy of vaccines, and as an adjuvant therapy that can enhance the therapeutic efficacy. The effect is expected to be high, which will greatly reduce the economic damage caused by livestock diseases in livestock farmers and strengthen competitiveness with imported veterinary drugs.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070054645A KR20080106789A (en) | 2007-06-04 | 2007-06-04 | Glycyrrhiza extracts increasing immunity of animals and method for preparing thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070054645A KR20080106789A (en) | 2007-06-04 | 2007-06-04 | Glycyrrhiza extracts increasing immunity of animals and method for preparing thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20080106789A true KR20080106789A (en) | 2008-12-09 |
Family
ID=40367376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070054645A KR20080106789A (en) | 2007-06-04 | 2007-06-04 | Glycyrrhiza extracts increasing immunity of animals and method for preparing thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20080106789A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011099812A3 (en) * | 2010-02-12 | 2011-12-29 | 한국생명공학연구원 | Composition for preventing or treating rotavirus infection containing licorice extract |
-
2007
- 2007-06-04 KR KR1020070054645A patent/KR20080106789A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011099812A3 (en) * | 2010-02-12 | 2011-12-29 | 한국생명공학연구원 | Composition for preventing or treating rotavirus infection containing licorice extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bandara et al. | Polyporus umbellatus, an edible-medicinal cultivated mushroom with multiple developed health-care products as food, medicine and cosmetics: a review | |
Krishnamoorthi et al. | Dietary nutrients in edible mushroom, Agaricus bisporus and their radical scavenging, antibacterial, and antifungal effects | |
US9662349B2 (en) | Dietary composition having mixed polysaccharides derived from lucid ganoderma, lycium barbarum and polygonatum sibiricum and method of its preparation | |
Pala et al. | Ethnomycological studies of some wild medicinal and edible mushrooms in the Kashmir Himalayas (India) | |
KR101718323B1 (en) | Pharmaceutical composition containing fermented Rhus verniciflua extracts for prevention or treatment of gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric mucosal injury | |
CN105802876B (en) | A kind of composite probiotics ferment clover tender shoots powder preparation and its preparation method and application | |
KR101013527B1 (en) | Ogapy[Acanthopanax]-mushroom mycelium fermentation products for preventing or treating gastrointestinal disease and Pharmaceutic uses thereof extract | |
KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
CN114306511A (en) | Compound composition and application thereof in preparing medicine for preventing and treating skin diseases caused by malassezia bacteria | |
KR20220020147A (en) | Method for preparing Phellinus linteus mycelia extract or Phellinus linteus mycelia extract powder and composition for enhancing immunity comprising them as an active ingredient | |
KR102095621B1 (en) | Method of manufacturing food additive | |
KR100814351B1 (en) | Physiologically active compositions of Basidiomycotina and Araliaceae extracts | |
KR20080106789A (en) | Glycyrrhiza extracts increasing immunity of animals and method for preparing thereof | |
RU2314819C1 (en) | Curative-prophylactic probiotic agent | |
KR100951055B1 (en) | Extract of Codonopsis lanceolata for Strength of Animal's Immunity, Thereof Method and Use | |
KR20090021610A (en) | Extract of acer tegmentosum maxim ramulus for improving immunity of animals and the agent for improving immunity containing the same | |
JP2002272267A (en) | Method for artificially culturing plant worm and extracted composition of isaria japonica and functional food using the same | |
KR101082599B1 (en) | Compositions for antioxidant and anticancer of the stomach using Pholiota nameko and functional mushroom jelly thereof | |
KR102095620B1 (en) | Food Additive and Natural Functional Food | |
CN112043730A (en) | Traditional Chinese medicine biological preparation for preventing and treating animal epidemic diseases | |
KR20070034801A (en) | Preparation of Chaga Fermented Beverage with High Hazardous Oxygen Removal Capacity | |
KR20080093488A (en) | An extract from bupleuri radix having improved immunity capability of animals and its use | |
KR20080114231A (en) | An extract from zanthoxylli fructus crust having improved immunity capability of animals, a method for preparing thereof, and its use | |
KR101723103B1 (en) | A composition comprising fermented artemisia annua extract and fermented red ginseng concentrated powder for preventing, improving or treating inflammation induced virulence of oral bacteria | |
KR100850365B1 (en) | Extract of cinnamoni ramulus stimulating immunity of animals and the extracting method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |